Form 4: OnKure Therapeutics Director Michael G. Grey Granted Stock Options

OnKure Therapeutics, Inc. director Michael G. Grey was granted 7,650 stock options with an exercise price of $2.44, vesting by May 28, 2026, or the next annual meeting.

Summary

• Michael G. Grey, a Director of OnKure Therapeutics, Inc. (OKUR), was granted 7,650 stock options.
• The options have an exercise price of $2.44 per share.
• The options were granted on May 28, 2025.
• 100% of the shares subject to the option will vest on the earlier of May 28, 2026, or the day prior to the Issuer's next annual meeting of stockholders.
• Vesting is contingent upon Mr. Grey continuing as a service provider through the applicable vesting date.
• The options expire on May 27, 2035.
• Following this transaction, Mr. Grey beneficially owns 7,650 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard practice that aligns interests and incentivizes long-term commitment, which is generally a positive signal for corporate governance and stability, though it's a routine disclosure rather than a major positive event.

Positives

• The grant of stock options to a director aligns the director's interests with those of the shareholders, incentivizing long-term performance.
• The vesting schedule encourages continued service and commitment from the director.

Negatives

• The issuance of new stock options can lead to minor dilution for existing shareholders if exercised, though this is a standard compensation practice.

Risks

• The value of the stock options is dependent on the future stock price of OnKure Therapeutics, Inc.
• If the stock price does not exceed the exercise price of $2.44, the options may not be 'in the money' and could expire worthless.
• Vesting is subject to the reporting person continuing as a service provider, meaning the options could be forfeited if service ceases before vesting.

Future Outlook

The stock options are subject to a vesting schedule, with 100% vesting on the earlier of May 28, 2026, or the day prior to the Issuer's next annual meeting of stockholders, provided the reporting person continues as a service provider. The options have a long-term expiration date of May 27, 2035, indicating a long-term incentive.

Management Comments

• "100% of the shares subject to the option will vest on the earlier of May 28, 2026 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date."

Industry Context

The grant of stock options to directors is a common practice across various industries, including biotechnology and pharmaceuticals, to attract, retain, and incentivize key personnel by aligning their financial interests with the long-term performance of the company. This specific filing does not provide broader industry trends or competitive analysis.

Comparison to Industry Standards

• The grant of stock options to directors is a standard compensation practice in publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule (typically 1-3 years for initial grants or annual grants) and the 10-year expiration period are generally consistent with industry norms for executive and director equity compensation.
• Specific comparable companies or projects are not mentioned in this filing, as it is a routine individual transaction disclosure.

Corporate Governance

Related Party Transactions

• The grant of stock options to Michael G. Grey, a director of OnKure Therapeutics, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders by incentivizing stock price appreciation. However, it also represents potential future dilution if the options are exercised.
• Employees: No direct impact on general employees mentioned.
• Customers: No direct impact on customers mentioned.
• Suppliers: No direct impact on suppliers mentioned.
• Creditors: No direct impact on creditors mentioned.

Next Steps

• The stock options will vest on the earlier of May 28, 2026, or the day prior to the Issuer's next annual meeting of stockholders, subject to continued service.
• Michael G. Grey may choose to exercise these options at any time after vesting and before the expiration date of May 27, 2035.

Key Dates

Keywords

OnKure Therapeutics, OKUR, Stock Options, SEC Form 4, Director Compensation, Equity Grant, Beneficial Ownership, Vesting Schedule, Michael G. Grey